Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis

PLoS Neglected Tropical Diseases

Volumn 11, Issue 5, 2017, Pages

  Devine, Angela ^a,b   Parmiter, Minnie ^c   Chu, Cindy S ^b,d   Bancone, Germana ^b,d   Nosten, François ^b,d   Price, Ric N ^b,e   Lubell, Yoel ^a,b   Yeung, Shunmay ^f  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; PRIMAQUINE; ANTIMALARIAL AGENT;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DRUG COST; DRUG SCREENING; FEMALE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE TEST; GROSS NATIONAL PRODUCT; HEMOLYSIS; HUMAN; MALE; MORTALITY RATE; ONLINE SYSTEM; PLASMODIUM VIVAX MALARIA; QUALITY OF LIFE; RECURRENT DISEASE; SENSITIVITY ANALYSIS; WEB BASED APPLICATION; ECONOMICS; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; MALARIA, VIVAX; MYANMAR; PREGNANCY; PROCEDURES; THAILAND; YOUNG ADULT;

ADULT; ANTIMALARIALS; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; FEMALE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; MALARIA, VIVAX; MALE; MYANMAR; PREGNANCY; PRIMAQUINE; THAILAND; YOUNG ADULT;

EID: 85017019631     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005602     Document Type: Article

References (44)

1. Price RN, Douglas NM, Anstey NM, New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Current opinion in infectious diseases. 2009.
2. Rahimi BA, Thakkinstian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W, Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J. 2014;13:481. doi: 10.1186/1475-2875-13-481 25486908
3. Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999–2011: an observational study. PLoS Med. 2013;10(3):e1001398. doi: 10.1371/journal.pmed.1001398 23472056
4. World Health OrganizationWorld malaria report: 2013. Geneva; 2013.
5. Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR, Sugiarto P, et al. Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study. PLoS Med. 2013;10(12):e1001575; discussion e. doi: 10.1371/journal.pmed.1001575 24358031
6. Douglas NM, Pontororing GJ, Lampah DA, Yeo TW, Kenangalem E, Poespoprodjo JR, et al. Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC medicine. 2014;12:217. doi: 10.1186/s12916-014-0217-z 25406857
7. Adekunle AI, Pinkevych M, McGready R, Luxemburger C, White LJ, Nosten F, et al. Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo. PLoS Negl Trop Dis. 2015;9(3):e0003595. doi: 10.1371/journal.pntd.0003595 25780913
8. Cappellini MD, Fiorelli G, Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64–74. doi: 10.1016/S0140-6736(08)60073-2 18177777
9. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI, G6PD deficiency: global distribution, genetic variants and primaquine therapy. Advances in parasitology. 2013;81:133–201. doi: 10.1016/B978-0-12-407826-0.00004-7 23384623
10. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9(11):e1001339. doi: 10.1371/journal.pmed.1001339 23152723
11. Ashley EA, Recht J, White NJ, Primaquine: the risks and the benefits. Malar J. 2014;13:418. doi: 10.1186/1475-2875-13-418 25363455
12. Bassat Q, Velarde M, Mueller I, Lin J, Leslie T, Wongsrichanalai C, et al. Key Knowledge Gaps for Plasmodium vivax Control and Elimination. The American journal of tropical medicine and hygiene. 2016.
13. World Health OrganizationControl and elimination of plasmodium vivax malaria: a technical brief. Geneva; 2015.
14. Luzzatto L, Seneca E, G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. British journal of haematology. 2014;164(4):469–80. doi: 10.1111/bjh.12665 24372186
15. Brito MA, Peixoto HM, Almeida AC, Oliveira MR, Romero GA, Moura-Neto JP, et al. Validation of the rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon. Revista da Sociedade Brasileira de Medicina Tropical. 2016;49(4):446–55. doi: 10.1590/0037-8682-0134-2016 27598631
16. Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW, Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Translational research: the journal of laboratory and clinical medicine. 2015;165(6):677–88.
17. Satyagraha AW, Sadhewa A, Elvira R, Elyazar I, Feriandika D, Antonjaya U, et al. Assessment of Point-of-Care Diagnostics for G6PD Deficiency in Malaria Endemic Rural Eastern Indonesia. PLoS Negl Trop Dis. 2016;10(2):e0004457. doi: 10.1371/journal.pntd.0004457 26894297
18. Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak P, Charunwatthana P, et al. Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests. The American journal of tropical medicine and hygiene. 2015;92(4):818–24. doi: 10.4269/ajtmh.14-0696 25646252
19. Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, et al. Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects. The American journal of tropical medicine and hygiene. 2015;92(1):22–7. doi: 10.4269/ajtmh.14-0298 25385861
20. Baird JK, Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency. BMC medicine. 2015;13(1):296.
21. Claxton K, Revill P, Sculpher M, Wilkinson T, Cairns J, Briggs A, The Gates Reference Case for Economic Evaluation. The Bill & Melinda Gates Foundation; 2014.
22. R Core TeamR: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.
23. University of OxfordStudy on the Treatment of Vivax Malaria (VHX) In: ClinicalTrialsgov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 [cited 2016 March 15]. https://clinicaltrials.gov/ct2/show/NCT01074905?term=efficacy+chloroquine+artesunate+primaquine&rank=1 NLM Identifier: NCT01074905.
24. Bancone G, Chu CS, Somsakchaicharoen R, Chowwiwat N, Parker DM, Charunwatthana P, et al. Characterization of G6PD genotypes and phenotypes on the northwestern Thailand-Myanmar border. PLoS One. 2014;9(12):e116063. doi: 10.1371/journal.pone.0116063 25536053
25. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144. doi: 10.1186/1475-2875-13-144 24731298
26. World Health OrganisationGuidelines for the Treatment of Malaria. Geneva; 2015.
27. Pamba A, Richardson ND, Carter N, Duparc S, Premji Z, Tiono AB, et al. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood. 2012;120(20):4123–33. doi: 10.1182/blood-2012-03-416032 22993389
28. Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, et al. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. PLoS Med. 2017;14(2):e1002224. doi: 10.1371/journal.pmed.1002224 28170391
29. Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malaria Journal. 2015;14(1):377.
30. Lubell Y, Reyburn H, Mbakilwa H, Mwangi R, Chonya K, Whitty CJ, et al. The cost-effectiveness of parasitologic diagnosis for malaria-suspected patients in an era of combination therapy. The American journal of tropical medicine and hygiene. 2007;77(6 Suppl):128–32. 18165484
31. MSH (Management Sciences for Health)International Drug Price Indicator Guide, 2014 Edition. Medford, Mass.; 2015.
32. Kyaw SS, Drake T, Thi A, Kyaw MP, Hlaing T, Smithuis FM, et al. Malaria community health workers in Myanmar: a cost analysis. Malar J. 2016;15(1):41.
33. World Health Organisation. WHO-CHOICE unit cost estimates for service delivery: WHO; 2011 [http://www.who.int/choice/cost-effectiveness/inputs/health_service/en/.
34. Kyaw SS, Drake T, Ruangveerayuth R, Chierakul W, White NJ, Newton PN, et al. Cost of treating inpatient falciparum malaria on the Thai-Myanmar border. Malar J. 2014;13:416. doi: 10.1186/1475-2875-13-416 25351915
35. Mulligan J-A, Fox-Rushby JA, Adam T, Johns B, Mills A, Unit Costs of Health Care Inputs in Low and Middle Income Regions. 2005.
36. World Health Organization. Life tables by country: World Health Organization; 2014 [http://apps.who.int/gho/data/node.main.692?lang=en.
37. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et al. The anaemia of Plasmodium vivax malaria. Malar J. 2012;11(1):135.
38. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2129–43.
39. The World Bank. GDP per capita (current US$) for Myanmar 2015 [http://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=MM.
40. Ochalek J, Lomas J, Claxton K. Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data. University of York CHE Research Paper. 2015.
41. Bruxvoort K, Goodman C, Kachur SP, Schellenberg D, How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS One. 2014;9(1):e84555. doi: 10.1371/journal.pone.0084555 24465418
42. Peixoto HM, Brito MA, Romero GA, Monteiro WM, de Lacerda MV, de Oliveira MR, Cost-effectiveness analysis of rapid diagnostic tests for G6PD deficiency in patients with Plasmodium vivax malaria in the Brazilian Amazon. Malar J. 2016;15(1):82.
43. White MT, Yeung S, Patouillard E, Cibulskis R, Costs and Cost-Effectiveness of Plasmodium vivax Control. The American journal of tropical medicine and hygiene. 2016;95(6 Suppl):52–61. doi: 10.4269/ajtmh.16-0182 28025283
44. Roy M, Bouma MJ, Ionides EL, Dhiman RC, Pascual M, The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India. PLoS Negl Trop Dis. 2013;7(1):e1979. doi: 10.1371/journal.pntd.0001979 23326611